Literature DB >> 16214147

The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors.

Matthias Canault1, Franck Peiretti, Francis Kopp, Bernadette Bonardo, Marie-France Bonzi, Jean-Christophe Coudeyre, Marie-Christine Alessi, Irène Juhan-Vague, Gilles Nalbone.   

Abstract

TNF alpha converting enzyme (TACE) critically regulates the inflammatory processes as it releases from the cell surface several transmembrane proteins, including TNFalpha (TNF) and its receptors TNFR1 and TNFR2. We investigated the expression of TACE in atherosclerotic lesions of apolipoproteinE-deficient (apoE (-/-)) mice. Five-week-old apoE(-/-) male mice were fed a high-fat diet and examined at 5, 10, 15 and 25 weeks of age. A group of wild-type C57BL/6 mice (WT) fed the high-fat diet for 25 weeks was included. In apoE(-/-) mice, lesions progressed with time in both aortic sinus and arch, in which TACE immunostaining also increased particularly between 5 and 15 weeks. TACE expression was also observed in human atherosclerotic plaques. The plasma levels of soluble TNFR1 and TNFR2 rose with atherosclerosis. In the 25-week-old WT mice, no lesions were observed and the plasma levels of TNFRs were 17% of those of age-matched apoE(-/-) mice. Incubated aortas of 25-week-old apoE(-/-) mice released much higher amounts of sTNF and sTNFRs than did aortas of 5-week-old apoE(-/-) mice or 25-week-old WT mice. Active TACE was expressed at the surface of macrophages isolated from apoE(-/-) mice. In conclusion, TACE expression is associated with lesions in atherosclerosis-prone sites. Our data suggest that atherosclerotic lesions-expressing TACE may contribute to the elevated levels of circulating sTNFRs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214147     DOI: 10.1016/j.atherosclerosis.2005.08.031

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  34 in total

Review 1.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

2.  Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II.

Authors:  Takehiko Takayanagi; Steven J Forrester; Tatsuo Kawai; Takashi Obama; Toshiyuki Tsuji; Katherine J Elliott; Elisa Nuti; Armando Rossello; Hang Fai Kwok; Rosario Scalia; Victor Rizzo; Satoru Eguchi
Journal:  Hypertension       Date:  2016-08-01       Impact factor: 10.190

3.  A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature.

Authors:  Akira Takaguri; Keita Kimura; Akinari Hinoki; Allison M Bourne; Michael V Autieri; Satoru Eguchi
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

4.  Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1.

Authors:  Matthias Canault; Aurélie S Leroyer; Franck Peiretti; Guy Lesèche; Alain Tedgui; Bernadette Bonardo; Marie-Christine Alessi; Chantal M Boulanger; Gilles Nalbone
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

Review 5.  Mechanisms and consequences of macrophage apoptosis in atherosclerosis.

Authors:  Tracie Seimon; Ira Tabas
Journal:  J Lipid Res       Date:  2008-10-25       Impact factor: 5.922

6.  Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice.

Authors:  Edward Thorp; Dongying Cui; Dorien M Schrijvers; George Kuriakose; Ira Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-01       Impact factor: 8.311

7.  Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice.

Authors:  Lesca M Holdt; Joachim Thiery; Jan L Breslow; Daniel Teupser
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-20       Impact factor: 8.311

8.  TNF receptors differentially signal and are differentially expressed and regulated in the human heart.

Authors:  R S Al-Lamki; A P Brookes; J Wang; M J Reid; J Parameshwar; M J Goddard; G Tellides; T Wan; W Min; J S Pober; J R Bradley
Journal:  Am J Transplant       Date:  2009-09-25       Impact factor: 8.086

9.  ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells.

Authors:  Katherine J Elliott; Allison M Bourne; Takehiko Takayanagi; Akira Takaguri; Tomonori Kobayashi; Kunie Eguchi; Satoru Eguchi
Journal:  J Mol Cell Cardiol       Date:  2013-05-17       Impact factor: 5.000

10.  Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-α Inhibition.

Authors:  Lin Zhu; Ilaria Giunzioni; Hagai Tavori; Roman Covarrubias; Lei Ding; Youmin Zhang; Michelle Ormseth; Amy S Major; John M Stafford; MacRae F Linton; Sergio Fazio
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-06-30       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.